171 related articles for article (PubMed ID: 38613207)
1. Expression and prognostic significance of the PD-1/PD-L1 pathway in AIDS-related non-Hodgkin lymphoma.
Zhao H; Cai S; Xiao Y; Xia M; Chen H; Xie Z; Tang X; He H; Peng J; Chen J
Cancer Med; 2024 Apr; 13(7):e7195. PubMed ID: 38613207
[TBL] [Abstract][Full Text] [Related]
2. Epstein-Barr virus genome in non-Hodgkin's lymphomas occurring in immunocompetent patients: highest prevalence in nonlymphoblastic T-cell lymphoma and correlation with a poor prognosis. Danish Lymphoma Study Group, LYFO.
d'Amore F; Johansen P; Houmand A; Weisenburger DD; Mortensen LS
Blood; 1996 Feb; 87(3):1045-55. PubMed ID: 8562929
[TBL] [Abstract][Full Text] [Related]
3. Clinicopathological characteristics and prognosis of Epstein-Barr virus-associated gastric cancer.
Li LL; Yu AY; Zhu M; Ma LY; Cao MH; Liu WL; Qin XB; Gao C; Han ZX; Wang HM
Arch Virol; 2024 May; 169(5):114. PubMed ID: 38700535
[TBL] [Abstract][Full Text] [Related]
4. Programmed cell death ligand 1 expression in aggressive pediatric non-Hodgkin lymphomas: frequency, genetic mechanisms, and clinical significance.
Fisher KE; Ferguson LS; Coffey AM; Merritt BY; Curry JL; Marcogliese AN; Major AM; Kamdar KY; Lopez-Terrada DH; Curry CV
Haematologica; 2022 Aug; 107(8):1880-1890. PubMed ID: 35081690
[TBL] [Abstract][Full Text] [Related]
5. The perivascular microenvironment in Epstein-Barr virus positive primary central nervous system lymphoma: The role of programmed cell death 1 and programmed cell death ligand 1.
Sugita Y; Furuta T; Ohshima K; Komaki S; Miyoshi J; Morioka M; Abe H; Nozawa T; Fujii Y; Takahashi H; Kakita A
Neuropathology; 2018 Apr; 38(2):125-134. PubMed ID: 29067721
[TBL] [Abstract][Full Text] [Related]
6. Enhanced PD-L1 Expression in LMP1-positive Cells of Epstein-Barr Virus-associated Malignant Lymphomas and Lymphoproliferative Disorders: A Single-cell Resolution Analysis With Multiplex Fluorescence Immunohistochemistry and In Situ Hybridization.
Kume A; Shinozaki-Ushiku A; Kunita A; Kondo A; Ushiku T
Am J Surg Pathol; 2022 Oct; 46(10):1386-1396. PubMed ID: 35605962
[TBL] [Abstract][Full Text] [Related]
7. Prevalence of Epstein-Barr Virus Infection and Mismatch Repair Protein Deficiency and the Correlation of Immune Markers in Tibetan Patients with Gastric Cancer.
Shi J; Yang X; Wang X; Luo Y; Zhou W; Luo H; Bianba Z; Nima Z; Wang Q; Wang H; Liao R; Ciren Q; Li M; Pang J
Biomed Res Int; 2022; 2022():2684065. PubMed ID: 35734348
[TBL] [Abstract][Full Text] [Related]
8. Association of PD-1/PD-L1 expression and Epstein--Barr virus infection in patients with invasive breast cancer.
Zhang WT; Zhu GL; Xu WQ; Zhang W; Wang HZ; Wang YB; Li YX
Diagn Pathol; 2022 Jul; 17(1):61. PubMed ID: 35842661
[TBL] [Abstract][Full Text] [Related]
9. Clinicopathological evaluation of the programmed cell death 1 (PD1)/programmed cell death-ligand 1 (PD-L1) axis in post-transplant lymphoproliferative disorders: association with Epstein-Barr virus, PD-L1 copy number alterations, and outcome.
Veloza L; Teixido C; Castrejon N; Climent F; Carrió A; Marginet M; Soldini D; González-Farré B; Ribera-Cortada I; Lopez-Guillermo A; González-Barca E; Sierra A; Herrera M; Gómez C; Garcia A; Balagué O; Campo E; Martinez A
Histopathology; 2019 Dec; 75(6):799-812. PubMed ID: 30861172
[TBL] [Abstract][Full Text] [Related]
10. Programmed death-1 (PD-1), programmed death-ligand 1 (PD-L1), and EBV-encoded RNA (EBER) expression in Hodgkin lymphoma.
Paydas S; Bağır E; Seydaoglu G; Ercolak V; Ergin M
Ann Hematol; 2015 Sep; 94(9):1545-52. PubMed ID: 26004934
[TBL] [Abstract][Full Text] [Related]
11. Analysis of Epstein-Barr Virus (EBV) and PD-L1 Expression in Nasopharyngeal Carcinoma Patients in a Non-Endemic Region.
Dias JM; Santana IVV; da Silva VD; Carvalho AL; Arantes LMRB
Int J Mol Sci; 2022 Oct; 23(19):. PubMed ID: 36233023
[TBL] [Abstract][Full Text] [Related]
12. Frequent structural variations involving programmed death ligands in Epstein-Barr virus-associated lymphomas.
Kataoka K; Miyoshi H; Sakata S; Dobashi A; Couronné L; Kogure Y; Sato Y; Nishida K; Gion Y; Shiraishi Y; Tanaka H; Chiba K; Watatani Y; Kakiuchi N; Shiozawa Y; Yoshizato T; Yoshida K; Makishima H; Sanada M; Onozawa M; Teshima T; Yoshiki Y; Ishida T; Suzuki K; Shimada K; Tomita A; Kato M; Ota Y; Izutsu K; Demachi-Okamura A; Akatsuka Y; Miyano S; Yoshino T; Gaulard P; Hermine O; Takeuchi K; Ohshima K; Ogawa S
Leukemia; 2019 Jul; 33(7):1687-1699. PubMed ID: 30683910
[TBL] [Abstract][Full Text] [Related]
13. Clinicopathologic features, tumor immune microenvironment and genomic landscape of Epstein-Barr virus-associated intrahepatic cholangiocarcinoma.
Huang YH; Zhang CZ; Huang QS; Yeong J; Wang F; Yang X; He YF; Zhang XL; Zhang H; Chen SL; Zheng YL; Deng R; Lin CS; Yang MM; Li Y; Jiang C; Kin-Wah Lee T; Ma S; Zeng MS; Yun JP
J Hepatol; 2021 Apr; 74(4):838-849. PubMed ID: 33212090
[TBL] [Abstract][Full Text] [Related]
14. PD-1 and PD-L1 gene expressions and their association with Epstein-Barr virus infection in chronic lymphocytic leukemia.
Gamaleldin MA; Ghallab OM; Nadwan EA; Abo Elwafa RA
Clin Transl Oncol; 2021 Nov; 23(11):2309-2322. PubMed ID: 34120295
[TBL] [Abstract][Full Text] [Related]
15. Clinicopathologic Analysis of Primary Adrenal Diffuse Large B-Cell Lymphoma: A Reappraisal of 23 Japanese Patients Based on EBV Association and PD-L1 Expression in Tumor Cells.
Kawano T; Tsuyuki Y; Suzuki Y; Shimada K; Kato S; Takahara T; Mori M; Nakaguro M; Sakakibara A; Nakamura S; Satou A
Am J Surg Pathol; 2021 Dec; 45(12):1606-1615. PubMed ID: 34534136
[TBL] [Abstract][Full Text] [Related]
16. The Triple Positivity for EBV, PD-1, and PD-L1 Identifies a Very High Risk Classical Hodgkin Lymphoma.
Ozturk V; Yikilmaz AS; Kilicarslan A; Bakanay SM; Akinci S; Dilek İ
Clin Lymphoma Myeloma Leuk; 2020 Jul; 20(7):e375-e381. PubMed ID: 32295735
[TBL] [Abstract][Full Text] [Related]
17. [PD-L1 expression in EBV-associated gastric carcinomas].
Danilova NV; Sotnikova TN; Kalinin DV; Oleynikova NA; Chayka AV; Khomyakov VM; Kakotkin VV; Vychuzhanin DV; Andreeva YY; Malkov PG
Arkh Patol; 2022; 84(4):5-12. PubMed ID: 35880594
[TBL] [Abstract][Full Text] [Related]
18. Comparison of Efficacy of Pembrolizumab between Epstein-Barr Virus‒Positive and ‒Negative Relapsed or Refractory Non-Hodgkin Lymphomas.
Kim SJ; Hyeon J; Cho I; Ko YH; Kim WS
Cancer Res Treat; 2019 Apr; 51(2):611-622. PubMed ID: 30025443
[TBL] [Abstract][Full Text] [Related]
19. CD68-positive tumour associated macrophages, PD-L1 expression, and EBV latent infection in a high HIV-prevalent South African cohort of Hodgkin lymphoma patients.
Antel K; Chetty D; Oosthuizen J; Mohamed Z; Van der Vyver L; Verburgh E
Pathology; 2021 Aug; 53(5):628-634. PubMed ID: 33558066
[TBL] [Abstract][Full Text] [Related]
20. Transcriptional analysis of immune genes in Epstein-Barr virus-associated gastric cancer and association with clinical outcomes.
Sundar R; Qamra A; Tan ALK; Zhang S; Ng CCY; Teh BT; Lee J; Kim KM; Tan P
Gastric Cancer; 2018 Nov; 21(6):1064-1070. PubMed ID: 29915957
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
